HCM - HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting | Benzinga
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology ("ASCO") Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online.
Results will be presented from the registration Phase II study of fruquintinib combined with sintilimab in 98 second-line or above patients with endometrial cancer ("EMC") with pMMR status by central laboratory analysis, which supported the New Drug Application (NDA) filed in China. The primary endpoint was objective response rate ("ORR") per RECIST v1.1, assessed by an independent review committee. The combination showed meaningful efficacy improvements in advanced EMC patients with pMMR status, regardless of prior bevacizumab treatment, with a manageable safety profile. The median follow-up time was 15.7 months. The ORR in 87 efficacy evaluable patients was 35.6% including two complete responses. Disease control rate ("DCR") was 88.5%, and duration of response was not reached, with 80.7% remaining in response after nine months. Amongst the 98 patients, median progression-free survival (PFS) was 9.5 months, and median overall survival (OS) was 21.3 months. Further details are available in the abstract link below.
Following the initial data of the FRUTIGA Phase III study of fruquintinib in second-line gastric cancer published during the February 2024 ASCO Plenary Series session, further updated efficacy data in key subgroups, and quality of life data will be presented at this year's ASCO annual meeting. In addition, further data from the FRESCO and FRESCO-2 Phase III colorectal cancer studies, the study of surufatinib combinations in small cell lung cancer, and initial clinical data for the ERK1/2 inhibitor HMPL-295 will be presented.
Details of the presentations, including links to available abstracts, are as follows:
| Abstract title |
| Presenter / Lead author |
| Presentation details |
SPONSORED STUDIES |
| Fruquintinib plus Sintilimab in Treated Advanced Endometrial Cancer (EMC) Patients (Pts) with pMMR Status: Results From a Multicenter, Single-Arm Phase 2 Study |
| Xiaohua Wu, Fudan University Shanghai Cancer Center, Shanghai, China |
| #5619 Poster Session - Gynecologic Cancer |
| Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2 |
| Tanios S. Bekaii-Saab, Mayo Clinic, U.S. |
| #3579 Poster Session - Gastrointestinal Cancer — Colorectal and Anal |
| Fruquintinib in Refractory Metastatic Colorectal Cancer |
| Cathy Eng, Vanderbilt-Ingram Cancer Center, U.S. |
| Link Education Session: New Drugs in Oncology: Incorporation Into Practice |
| Updates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study |
| Feng Wang, Sun Yat-Sen University Cancer Center, Guangzhou, China |
| Link Education Session: ASCO Plenary Series: Rapid Abstract Updates |
| Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) |
| Yi Hu, Chinese PLA General Hospital, Beijing, China |
| #e15109 Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology |
| First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: dose-escalation results of monotherapy |
| Xianjun Yu, Fudan University Shanghai Cancer Center, Shanghai, China |
| #e15112 Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology |
INVESTIGATOR-INITIATED STUDIES |
| Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE) |
| Chen Yajie, Zhang Zhen, Fudan University Shanghai Cancer Center, Shanghai, China |
| #e15570 Publication Only: Gastrointestinal Cancer—Colorectal and Anal |
| A propensity score matched comparison ... |